Tags: Drug.

PEAQX is a competitive antagonist at the NMDA receptor. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors more detailed studies of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent anticonvulsant in animal tests.

PEAQX.png
IUPAC name
([(1S)-1-(4-bromophenyl)ethyl]amino-(23-dioxo-14-dihydroquinoxalin-5-yl)methyl)phosphonic acid

Loading...

This page contains content from the copyrighted Wikipedia article "PEAQX"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.